Roivant 2Q 2026 Earnings Call - ROIVANT SCIENCES LTD

Financial Performance:

• Reported net revenue of $31 million for Q2 2026 (five weeks post-approval for Lysriah), reflecting strong initial demand and broad prescriber adoption.
• Reported adjusted loss from continuing operations of $133 million (non-GAAP) and GAAP loss of $153 million.
• Cash and cash equivalents stood at $4.2 billion as of September 30, 2026, bolstered by proceeds from the Moderna litigation settlement.
• Share repurchases totaled approximately $280 million (9.4 million shares) over the six-month period ended September 30.
• Revenue recognition reflects sales to specialty pharmacies; significant undispensed inventory held by pharmacies at quarter-end has since been dispensed.
• Management noted inventory dynamics created a modest tailwind for the September quarter and a potential modest headwind for the December quarter, expected to normalize by 2027.

Guidance and Future Outlook:

• 2027 is projected to be a high-volume year with multiple program milestones, including SNDA filing for NIU, potential new Brepo indications, and top-line data for IMVG-1402 (RA) and Graves' disease.
• Company confirmed ongoing FDA discussions regarding IMVG-1402 for Rheumatoid Arthritis, with plans to update trial strategies later this year or early next year.
• Enrollment for Graves' disease studies is reported as strong; specific timing for data readouts is expected to be shared in the near future.
• Future Moseley-Sigawatt (brexpiprazole) development plans include aggressive exploration of additional pulmonary hypertension indications (IPF, PAH, PP) pending regulatory alignment.
• Investor Day scheduled for December 9, 2026, will provide deep dives into commercial opportunities for NIU and RA.

Business Segments and Product Lines:

• Lysriah (Dermatomyositis): Commercially launched in August 2026; hundreds of patients on paid drug with hundreds of initial prescriptions; payer dynamics remain generally straightforward despite emerging access controls.
• IMVG-1402 (Rheumatoid Arthritis): Period 2 data showed 92.5% of patients maintained ACR20 response vs. 75% on placebo; 600mg dose significantly outperformed 300mg dose (which was similar to placebo), confirming the need for deep IgG suppression.
• Brepo (NIU): Clinical data demonstrated sustained efficacy with 67% of patients achieving steroid-free quiescence; met all primary and secondary endpoints; no median treatment failure observed over 48 weeks.
• Moseley-Sigawatt (PHILD): Phase 3 study underway; Phase 2 data showed a 56% placebo-adjusted reduction in PVR and significant improvements in six-minute walk distance and cardiac hemodynamics.
• Sjogren's: Program unlikely to progress based on futility analyses and competitor data; will run existing Phase 2 to completion to gather insights.
• Pipeline: Continued focus on expanding indications for existing assets, including potential new indications for Brepo and Moseley-Sigawatt.

Market and Competitive Landscape:

• RA: Targeting a difficult-to-treat population of ~85,000 U.S. patients who have failed TNF, JAK inhibitors, and IL-6 therapies; unmet need highlighted by the recent safety-related pause of a competitor (Martiva) in this space.
• NIU: Identified as a poorly served indication and the third leading cause of blindness; positioned to set a new standard of care for non-steroidal therapy.
• PHILD: Addresses a disease with a 1.5–2 year median survival; Moseley-Sigawatt offers the first non-trials-approved therapy option with deep PVR reduction.
• Competition: Management noted competitor data in Sjogren's and Novartis/Amgen activities in related space; Lysriah is seeing patients switching from off-label JAKs, IVIG, and steroids.

Risks and Challenges:

• Regulatory Uncertainty: Final FDA approval pathway, endpoint selection, and trial design for RA (IMVG-1402) remain subject to ongoing discussions.
• Payer Dynamics: While initial uptake is strong, management anticipates increasing payer restrictions and access controls in the future.
• Competitive Landscape: Rapidly evolving competition in Sjogren's and RA; futility of prior competitor programs highlights the difficulty of the RA market.
• Inventory Management: Early commercial launch inventory dynamics caused temporary revenue recognition timing differences (undispensed drug at quarter-end).
• Clinical Failure: The decision to de-prioritize Sjogren's underscores the risk of insufficient clinical differentiation or efficacy in autoimmune indications.

Management Commentary and Tone:

• Tone was highly confident and celebratory, describing 2026 as a "phenomenal," "transformational," and "incredible year."
• CEO Matt Klein emphasized the "high bar" set by Lysriah launch and NIU data, yet expressed optimism for 2027 driven by multiple top-line data points.
• Management highlighted the "privat team" execution and the deep clinical unmet need as key drivers of success.
• Confidence was explicitly stated in the ability to navigate FDA discussions for RA due to the high quality of the data set.

Analyst Questions and Answers:

• Lysriah Uptake: Management clarified that "paid" revenue includes all prescriptions dispensed; hundreds of patients are on paid drug, with broad access despite some emerging payer restrictions.
• IMVG-1402 Dosing: Confirmed that 300mg was insufficient to maintain response, reinforcing the thesis that deep IgG suppression (achieved at 600mg) is critical for efficacy in RA.
• RA Regulatory Path: Acknowledged uncertainty regarding whether a single Phase 3 trial will suffice; plans to propose an aggressive but reasonable plan to FDA.
• Sjogren's Strategy: Confirmed no progression to Phase 3, citing futility in a large Phase 2 and lack of clinical differentiation; will finish existing study to learn.
• Moseley-Sigawatt Expansion: Committed to exploring multiple pulmonary hypertension indications (IPF, PAH) with potential Phase 2/3 starts in 2027.
• RA Trial Design: Indicated that future Phase 3 will likely be a parallel randomized controlled trial (RCT) rather than randomized withdrawal, though specifics are FDA-dependent.

Other Key Points:

• The company has completed its 2026 quarterly update cycle, with all major 2026 data points (NIU, PHILD, RA Period 2, Lysriah launch) now disclosed.
• Safety profile for IMVG-1402 remains consistent with mechanism, with no new safety signals and event rates comparable to placebo.
• Management highlighted the "autoantibody pathology" relevance in RA, suggesting a specific patient subset where the drug is highly effective.
• No specific U.S. patients from the IMVG-1402 OLE (Open Label Extension) transitioned directly to commercial Lysriah in the quarter; commercial uptake is driven by new and existing refractory patients.